Zepbound (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
Clinics 78:100305 Ott EC, Cavinder CA, Wang S, Smith T, Lemley CO, Dinh TT (2022) Oxidative stress biomarkers and free amino acid concentrations in the blood plasma of moderately exercised horses indicate adaptive response to prolonged exercise training
The skin may be mildly swollen and have a pink color for a few hours after treatment
Schedule prompt medical evaluation (within 24-48 hours) for: Gradually worsening shortness of breath over days to weeks Dyspnea with exertion that is new or significantly worse than baseline Breathing difficulty accompanied by persistent cough or fever Leg swelling, weight gain, or orthopnea (difficulty breathing when lying flat) Respiratory symptoms associated with severe ongoing nausea, vomiting, or inability to maintain hydration Patients should not discontinue GLP-1 medications without medical guidance (except in cases of suspected severe allergic reactions), but should contact their healthcare provider promptly to discuss respiratory symptoms
